AASLD 2014 - LB-3 - All-oral 12-week Combination Treatment with Daclatsvir (DCV) and Sofosbuvir (SOF) in Patients infected with HCV Genotype (GT) 3: ALLY-3 Phase 3 Study

AASLD 2014. LB-3. All-oral 12-week Combination Treatment with Daclatsvir (DCV) and Sofosbuvir (SOF) in Patients infected with HCV Genotype (GT) 3: ALLY-3 Phase 3 Study

D.R. Nelson et al.

Background: Options for treating HCV GT 3 infection are limited in both treatment-naïve and experienced patients; the only currently available all-oral regimen requires 24-week treatment that includes ribavirin (RBV). Newer combinations without RBV are being studied to shorten treatment duration. The efficacy and safety of the combination of DCV (potent, pangenotypic NS5A inhibitor) and SOF (NS5B polymerase inhibitor) for 12 weeks were evaluated in patients chronically infected with GT 3. 

Results:

Conclusion: This all-oral, RBV-free, 12-week combination of DCV+SOF in HCV GT 3 infection achieved SVR4 rates of 91% and 86% in treatment-naïve and experienced patients, respectively, with higher rates in those with METAVIR F0-F3. This combination was safe and well tolerated.

CARE Faculty Canadian Perspective:

The combination of sofosbuvir and daclatasvir for 12 weeks appears to provide a high SVR-4 at 96% in the non-cirrhotic cohort whether treatment naïve or experienced.  However, in persons with cirrhosis the SVR-4 rate is low at 63%.  This regimen, though not available in Canada presently, may in the future provide an alternative to the approved regimen of sofosbuvir and ribavirin for 24 weeks, in persons without cirrhosis.

Related Abstracts of Interest